[go: up one dir, main page]

MA33051B1 - Variants de liaison anti-albumine serique ameliores - Google Patents

Variants de liaison anti-albumine serique ameliores

Info

Publication number
MA33051B1
MA33051B1 MA34104A MA34104A MA33051B1 MA 33051 B1 MA33051 B1 MA 33051B1 MA 34104 A MA34104 A MA 34104A MA 34104 A MA34104 A MA 34104A MA 33051 B1 MA33051 B1 MA 33051B1
Authority
MA
Morocco
Prior art keywords
serum albumin
contrasts
albumin enhancer
antagonist
antagonist serum
Prior art date
Application number
MA34104A
Other languages
Arabic (ar)
English (en)
Inventor
Angelis Elena De
Carolyn Enever
Haiqun Liu
Christopher Plummer
Oliver Schon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33051B1 publication Critical patent/MA33051B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des variants améliorés du domaine variable unique DOM7h-14 de l'immunoglobuline anti-albumine sérique, ainsi que des ligands et des conjugués de médicaments contenant de tels variants, des compositions, des acides nucléiques, des vecteurs et des hôtes.
MA34104A 2009-02-19 2010-02-17 Variants de liaison anti-albumine serique ameliores MA33051B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16398709P 2009-03-27 2009-03-27
US24713609P 2009-09-30 2009-09-30
PCT/EP2010/052008 WO2010094723A2 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés

Publications (1)

Publication Number Publication Date
MA33051B1 true MA33051B1 (fr) 2012-02-01

Family

ID=42634270

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34104A MA33051B1 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine serique ameliores

Country Status (25)

Country Link
US (3) US9534043B2 (fr)
EP (3) EP3656788A3 (fr)
JP (2) JP5759391B2 (fr)
KR (1) KR101819754B1 (fr)
CN (1) CN102405233B (fr)
AR (1) AR075505A1 (fr)
AU (1) AU2010215482B2 (fr)
BR (1) BRPI1013341B1 (fr)
CA (2) CA3079184A1 (fr)
CL (1) CL2011002025A1 (fr)
CO (1) CO6410311A2 (fr)
DO (1) DOP2011000266A (fr)
EA (1) EA028178B1 (fr)
ES (2) ES2655071T3 (fr)
HK (1) HK1247944A1 (fr)
IL (1) IL214480A0 (fr)
MA (1) MA33051B1 (fr)
MX (1) MX2011008749A (fr)
NZ (1) NZ595242A (fr)
PE (1) PE20120001A1 (fr)
SG (1) SG173489A1 (fr)
TW (1) TW201042039A (fr)
UY (1) UY32450A (fr)
WO (1) WO2010094723A2 (fr)
ZA (1) ZA201105657B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595344A (en) * 2009-03-27 2013-09-27 Glaxo Group Ltd Drug fusions and conjugates
WO2011008814A2 (fr) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Mesure multiplexée d'adn endogène et exogène
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
CA2777312A1 (fr) * 2009-10-27 2011-05-05 Inusha De Silva Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
EP2571900A1 (fr) * 2010-05-20 2013-03-27 Glaxo Group Limited Variants de liaison anti-sérum-albumine améliorés
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
AU2011333738A1 (en) * 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
EP2646467A2 (fr) 2010-12-01 2013-10-09 Glaxo Group Limited Domaines variables améliorés à liaison unique d'anti-albumine sérique
WO2012104227A1 (fr) 2011-02-02 2012-08-09 Glaxo Group Limited Nouvelles protéines de liaison à un antigène
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
WO2018224439A1 (fr) * 2017-06-05 2018-12-13 Numab Innovation Ag Nouveaux anticorps anti-hsa
JP7130678B2 (ja) 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体
KR20250151445A (ko) 2023-02-17 2025-10-21 아블린쓰 엔.브이. 신생아 fc 수용체에 결합하는 폴리펩티드

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
EP1600459A3 (fr) 2002-06-28 2005-12-07 Domantis Limited Ligand
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP2172553A1 (fr) 2004-03-24 2010-04-07 Domantis Limited Sequence de tete universelle gas1
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
RU2428431C2 (ru) 2004-12-02 2011-09-10 Домантис Лимитед Слитые конструкции лекарственного средства и конъюгаты
WO2007066109A1 (fr) * 2005-12-06 2007-06-14 Domantis Limited Ligands bispecifiques ayant une specificite de liaison a des cibles de surface cellulaire et procedes d'utilisation de ceux-ci
CA2640066A1 (fr) 2006-01-24 2007-08-02 Roland Beckmann Proteines de fusion contenant des jonctions naturelles
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
MX2009013137A (es) * 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2010060486A1 (fr) 2008-11-26 2010-06-03 Glaxo Group Limited Ligands qui se lient à il-13
EP2398825B1 (fr) 2009-02-19 2017-10-25 Glaxo Group Limited Domaine variable unique anti-albumine serique
CA2750477A1 (fr) * 2009-02-19 2010-08-26 Stephen Duffield Polypeptides, domaines variables d'anticorps, et antagonistes ameliores, tous etant des anti-tnfr1
JP2012532619A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
JP2013528362A (ja) * 2010-04-21 2013-07-11 グラクソ グループ リミテッド 結合ドメイン

Also Published As

Publication number Publication date
CA3079184A1 (fr) 2010-08-26
US20200283512A1 (en) 2020-09-10
MX2011008749A (es) 2011-09-06
US20110305696A1 (en) 2011-12-15
TW201042039A (en) 2010-12-01
EP2398826A2 (fr) 2011-12-28
EA028178B1 (ru) 2017-10-31
JP2015204831A (ja) 2015-11-19
AU2010215482A1 (en) 2011-08-25
JP2012517820A (ja) 2012-08-09
ES2655071T3 (es) 2018-02-16
DOP2011000266A (es) 2011-12-31
NZ595242A (en) 2013-11-29
US10696738B2 (en) 2020-06-30
UY32450A (es) 2010-09-30
CN102405233A (zh) 2012-04-04
WO2010094723A2 (fr) 2010-08-26
AU2010215482B2 (en) 2014-02-13
CN102405233B (zh) 2014-11-26
CA2767752A1 (fr) 2010-08-26
ES2774192T3 (es) 2020-07-17
WO2010094723A3 (fr) 2011-04-21
PE20120001A1 (es) 2012-02-12
CL2011002025A1 (es) 2012-04-09
HK1247944A1 (en) 2018-10-05
KR101819754B1 (ko) 2018-01-18
BRPI1013341B1 (pt) 2021-09-08
US9534043B2 (en) 2017-01-03
CA2767752C (fr) 2020-07-07
EP3656788A3 (fr) 2020-07-29
ZA201105657B (en) 2012-04-25
EP2398826B1 (fr) 2017-10-25
BRPI1013341A2 (pt) 2016-10-11
CO6410311A2 (es) 2012-03-30
EP3656788A2 (fr) 2020-05-27
KR20110127223A (ko) 2011-11-24
US20170298121A1 (en) 2017-10-19
AR075505A1 (es) 2011-04-06
EP3330287A1 (fr) 2018-06-06
JP6100315B2 (ja) 2017-03-22
EA201171068A1 (ru) 2012-02-28
SG173489A1 (en) 2011-09-29
EP3330287B1 (fr) 2019-12-18
JP5759391B2 (ja) 2015-08-05
IL214480A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
MA33052B1 (fr) Variants de liaison anti-albumine sérique améliorés
MA33051B1 (fr) Variants de liaison anti-albumine serique ameliores
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
IN2012DN00640A (fr)
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EP2152290A4 (fr) Méthodes pour administrer des anticorps anti-il-5
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
EA201170441A1 (ru) Терапевтические противовирусные пептиды
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
CY1116251T1 (el) Συστηματα michael ως αναστολεις τρανσγλουταμινασων
MA37838A1 (fr) Immunoconjugués comprenant des anticorps anti-cd22
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.